English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background HIV-1 entry is a dynamic process with two main actors: HIV-1 envelope glycoproteins: gp120 and gp41. The entry is a key step of the infection: blockade of this step leads to an inhibition of the viral replication. Our main focus in this study is the key actor of the viral entry and fusion: gp41. Our goal is to develop HIV-1 entry inhibitors using two strategies: i) the development of immunogens capable to induce neutralizing antibodies, ii) the modeling and synthesize as monomeric or trimeric peptide inhibitors derived from the HR1 and HR2 regions of gp41.

Design of HR1 and HR2 synthetic peptide analogs: Characterization of their antiviral activities and their capacities to induce neutralizing antibodies